AbbVie today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older with moderate-to-severe plaque ...
At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.
Recommendation supported by unprecedented Phase 3 data, demonstrating that TECVAYLI® in combination with daratumumab achieved statistically significant improvements in progression-free and overall ...
USA News Group News Commentary ? In a remote corner of New Zealand's South Island, a goldfield that helped build the country more than a century ago is being reborn ? and this time, the story is about ...
SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval ...
Highlights: Santa Helena expansion programme discovers a second Au-Ag & Zn-Pb system of VMS mineralisation; New VMS layer of Au-Ag & Zn-Pb mineralisation intercepted below and east of Santa Helena ...
ESET researchers have discovered SprySOCKS for Windows, FishMonger’s backdoor weaponizing a kernel driver for advanced ...
True North Copper has stitched fresh scale into its Qld Cloncurry copper play, folding Mongoose into Taipan, chasing Wallace ...
Linux 7.1 is here to end the Intel 486 CPU era - and do some serious legacy clean up ...
True North Copper has consolidated its Cloncurry copper project by acquiring the adjacent Mongoose resource, combining the ...
Base case after-tax NPV 8% of C$ 4.6 billion , IRR of 24% , and payback period of 2.9 years , based on long-term commodity price assumptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results